Sugi Predict

Sugi Predict / Compounds / SCHEMBL601162

SCHEMBL601162

SCHEMBL601162

CCCCCCCCC(F)CF

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.46
▸ LMNA P02545 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ DNM1 Q05193 2/20 0.42
▸ OPRM1 P35372 1/20 0.40
▸ GPR84 Q9NQS5 3/20 0.38
▸ FDPS P14324 3/20 0.38
▸ SPHK1 Q9NYA1 1/20 0.38
▸ FFAR1 O14842 1/20 0.38
▸ CES2 O00748 1/20 0.38
▸ LCK P06239 1/20 0.37
▸ PPARD Q03181 1/20 0.37
▸ ZDHHC20 Q5W0Z9 1/20 0.37
▸ ZDHHC2 Q9UIJ5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20825525 1.00 MAPT (0.46) MAPTLMNATSHRTHRBDNM1
SCHEMBL28999169 1.00 MAPT (0.46) MAPTLMNATSHRTHRBDNM1
SCHEMBL28436352 1.00 MAPT (0.46) MAPTLMNATSHRTHRBDNM1
SCHEMBL812077 1.00 MAPT (0.46) MAPTLMNATSHRTHRBDNM1
SCHEMBL28999332 0.97 — —
SCHEMBL18428169 0.93 MAPT (0.42) MAPTLMNATSHRTHRBDNM1
SCHEMBL28999176 0.91 MAPT (0.41) MAPTLMNATSHRTHRBDNM1
SCHEMBL2942098 0.89 — —
SCHEMBL18327845 0.89 — —
SCHEMBL24926247 0.86 MAPT (0.52) MAPTLMNATSHRTHRBDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3986438-B1 P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES MERCK SHARP & DOHME LLC (US) 2025-04-16 — — EP disclosed
US-20250042961-A1 P53 PEPTIDOMIMETIC MACROCYCLES AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) 2025-02-06 — — US disclosed
US-20250034211-A1 C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX MERCK SHARP & DOHME LLC (US) 2025-01-30 — — US disclosed
CN-118829648-A P53 peptidomimetic macrocycles 默沙东有限责任公司 2024-10-22 — — CN disclosed
EP-4444740-A2 P53 PEPTIDOMIMETIC MACROCYCLES Merck Sharp & Dohme LLC (US) 2024-10-16 — — EP disclosed
EP-4441067-A1 C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX Merck Sharp & Dohme LLC (US) 2024-10-09 — — EP disclosed
WO-2024197199-A2 TARGETING PRAC1 IN STEROID HORMONE DRIVEN CANCER FRED HUTCHINSON CANCER CENTER (US) 2024-09-26 — — WO disclosed
US-20240124518-A1 METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS AILERON THERAPEUTICS INC (US) 2024-04-18 — — US disclosed
EP-3126375-B1 MACROCYCLIC PEPTIDOMIMETICS FOR ALPHA-HELIX MIMICRY UNIV ROCHESTER (US) 2023-12-13 — — EP disclosed
WO-2023107353-A2 P53 PEPTIDOMIMETIC MACROCYCLES MERCK SHARP & DOHME LLC (US) 2023-06-15 — — WO disclosed
US-20090275519-A1 Therapeutic peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2009-11-05 — — US disclosed
WO-2009126292-A2 BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2009-10-15 — — WO disclosed
EP-2094721-A1 BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS Aileron Therapeutics, Inc. (US) 2009-09-02 — — EP disclosed
WO-2009099677-A2 THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2009-08-13 — — WO disclosed
US-20090088553-A1 Bis-Sulfhydryl Macrocyclization Systems AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) 2009-04-02 — — US disclosed
US-20090047711-A1 BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS AILERON THERAPEUTICS, INC. (US) 2009-02-19 — — US disclosed
US-20080262200-A1 Triazole Macrocycle Systems AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) 2008-10-23 — — US disclosed
WO-2008104000-A2 TRIAZOLE MACROCYCLE SYSTEMS AILERON THERAPEUTICS, INC. (US) 2008-08-28 — — WO disclosed
WO-2008076904-A1 BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS AILERON THERAPEUTICS, INC. (US) 2008-06-26 — — WO disclosed
US-3933889-A 4,5-Cis-didehydro-PGF1.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262200-A1 Triazole Macrocycle Systems FLT3, VIP, NGLY1 MAPT 1904/4885LMNA 4013/4885TSHR 506/4885
US-20090088553-A1 Bis-Sulfhydryl Macrocyclization Systems CBS, HLCS, CTH MAPT 4024/4885LMNA 3708/4885TSHR 2584/4885
US-20090047711-A1 BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS CBS, HLCS, CTH MAPT 4024/4885LMNA 3708/4885TSHR 2584/4885
US-20240124518-A1 METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS VIP, NGLY1, IAPP MAPT 3949/4885LMNA 2092/4885TSHR 1829/4885
US-20250034211-A1 C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX TP53, MDM4, MDM2 MAPT 2489/4885LMNA 957/4885TSHR 2772/4885
US-20090275519-A1 Therapeutic peptidomimetic macrocycles PCNA, MKI67, NFATC1 MAPT 4252/4885LMNA 3809/4885TSHR 2398/4885
US-20250042961-A1 P53 PEPTIDOMIMETIC MACROCYCLES TP53, MDM2, MDM4 MAPT 3042/4885LMNA 1214/4885TSHR 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.